Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Caccese

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Anti-Cancer Drugs|January 4, 2021
Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case reportMarta Padovan, Mario Caccese, Vittorina Zagonel, et al.
Critical Reviews in Oncology/Hematology|March 2, 2019
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise reviewMario Caccese, Stefano Indraccolo, Vittorina Zagonel, et al.
Annals of Translational Medicine|October 29, 2019
Immune-checkpoint inhibitors in brain metastases from renal cell carcinoma: a battle was lost but not the warGiuseppe Lombardi, Marco Maruzzo, Giuseppe Minniti, et al.
The International Journal of Neuroscience|April 23, 2020
Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experienceMarco Zoccarato, Anna Maria Basile, Marta Padovan, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
Cancers|October 12, 2019
Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma PatientsGiuseppe Lombardi, Eleonora Bergo, Mario Caccese, et al.
Cancers|December 30, 2020
Recurrent Glioblastoma: From Molecular Landscape to New Treatment PerspectivesCristina Birzu, Pim French, Mario Caccese, et al.
Expert Review of Molecular Diagnostics|October 17, 2017
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune systemGiulia Grizzi, Mario Caccese, Anastasios Gkountakos, et al.
Anti-Cancer Drugs|August 10, 2022
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E -mutant and SOX2 amplificationGiulia Cerretti, Diego Cecchin, Luca Denaro, et al.
Current Radiopharmaceuticals|January 16, 2019
Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our ExperienceLaura Evangelista, Lea Cuppari, Luisa Bellu, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Anti-Cancer Drugs|January 4, 2021
Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case reportMarta Padovan, Mario Caccese, Vittorina Zagonel, et al.
Critical Reviews in Oncology/Hematology|March 2, 2019
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise reviewMario Caccese, Stefano Indraccolo, Vittorina Zagonel, et al.
Annals of Translational Medicine|October 29, 2019
Immune-checkpoint inhibitors in brain metastases from renal cell carcinoma: a battle was lost but not the warGiuseppe Lombardi, Marco Maruzzo, Giuseppe Minniti, et al.
The International Journal of Neuroscience|April 23, 2020
Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experienceMarco Zoccarato, Anna Maria Basile, Marta Padovan, et al.
Expert Opinion on Biological Therapy|July 21, 2015
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesLorenzo Calvetti, Sara Pilotto, Luisa Carbognin, et al.
Cancers|October 12, 2019
Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma PatientsGiuseppe Lombardi, Eleonora Bergo, Mario Caccese, et al.
Cancers|December 30, 2020
Recurrent Glioblastoma: From Molecular Landscape to New Treatment PerspectivesCristina Birzu, Pim French, Mario Caccese, et al.
Expert Review of Molecular Diagnostics|October 17, 2017
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune systemGiulia Grizzi, Mario Caccese, Anastasios Gkountakos, et al.
Anti-Cancer Drugs|August 10, 2022
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E -mutant and SOX2 amplificationGiulia Cerretti, Diego Cecchin, Luca Denaro, et al.
Current Radiopharmaceuticals|January 16, 2019
Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our ExperienceLaura Evangelista, Lea Cuppari, Luisa Bellu, et al.
Pageof 6